

12<sup>th</sup> Annual

# Global Healthcare Executive Summit

## Agenda

---

### Lunch & Check In

---

11:30 AM – 12:30 PM **Lunch & Check-In**  
Buffet Lunch (*Ballroom/Lounge*)

### Speakers & Panelists

---

12:30 PM – 12:55 PM **Welcome & Introduction: State of Our Global Platform**  
Banks Bourne (Bourne Partners)

1:00 PM – 1:15 PM **Strategic Capital Update**  
Minor Hinson (Bourne Partners Strategic Capital)

1:20 PM – 1:50 PM **Patient Centricity, Innovative Technology, and Site Engagement: What's Next for Clinical Trials?**  
Ella Grach (Eximia Research), Moisha Platto (Scout Clinical) | **Moderator:** Jake Curtis

1:55 PM – 2:40 PM **Networking Break #1**

2:40 PM – 2:55 PM **Portfolio Company Update: American Injectables**  
Travis Allen (American Injectables)

3:00 PM – 3:25 PM **Capital Markets Update**  
Jeremy Johnson (Bourne Partners)

3:30 PM – 4:00 PM **Biopharma Deal Structuring & Creative Financing**  
Dr. Gavin Spencer (Nicox), Asher M. Rubin (Sidley Austin, LLP), Matthew Bullard | **Moderator:** Oliver White

4:05 PM – 4:50 PM **Networking Break #2**

4:50 PM – 5:05 PM **Portfolio Company Update: PAI Pharma**  
Kurt Orlofski (PAI Pharma)

5:10 PM – 5:40 PM **The Rise of GLP1's and Their Impact Across the Healthcare Ecosystem**  
Dr. Pat Stephens (Hims & Hers), Dr. Carlos Jorge (Companion Health) | **Moderator:** Carson Riley

5:45 PM – 6:30 PM **Fireside Chat**  
John Chiminski (Catalent), Philip Macnabb (Curia) | **Moderator:** Banks Bourne

### Reception

---

6:30 PM – 7:30 PM **Networking Cocktail Reception**  
Pavilion Terrace

12<sup>th</sup> Annual

# Global Healthcare Executive Summit

## Speaker Biographies

---



### **Banks Bourne**

**Chief Executive Officer & Founder, Bourne Partners**

As Founder and CEO, Banks oversees all business operations and direct investment opportunities at Bourne Partners and Bourne Partners Strategic Capital. Under Banks' leadership, the firm has been party to more than \$10 billion of transactions in the Pharma, Pharma Services and Consumer Healthcare sectors having represented hundreds of closely held / entrepreneur led companies as well as those owned by many of the elite healthcare private equity funds.

Banks is the founder of Tanner Pharma Group, a pharma services company dedicated to providing managed access, commercialization and clinical trials services to patients and partners in more than 100 countries.

Currently, Banks is currently heavily involved in the firms' investments in PAI Pharma, CadenceRx, Carlin Consumer Health, Eximia Research, MedPharm, and American Injectables. He received a B.A. degree in Business Management from North Carolina State University and an M.B.A. from Wake Forest University. He is a member of Young Presidents Organization (YPO – Gold).

While Banks has derived great satisfaction by offering focused advisory services to, and investing in Pharma, Healthcare, and consumer-oriented companies that need strategic and operational insights; he is even more gratified by knowing that his work has helped companies to improve the health and well-being of patients across the world. He is passionate about providing healthcare and specifically pharmaceuticals to less fortunate patients, as demonstrated by supporting The Bourne Foundation, The Max Foundation and other non-profit organizations. In addition to his passion for a sub-80 round of golf and fresh ski powder, Banks enjoys traveling to new and interesting destinations and spending time with his wife (Molly) and children (Fairbanks and Mary Pope).



## Minor Hinson

**Head of Private Equity, Senior Managing Director/CIO, Bourne Partners Strategic Capital**

Since starting at Bourne Partners in 2011, Minor has been responsible for direct private equity and fund investment activities. and has been very involved in both the Phoenix Therapeutics, Inc. joint venture with The Carlyle Group, as well as with the creation, management, and asset disposition of Covis Pharma S.à.r.l (“Covis”). Minor also served on the U.S. Board of Covis from inception to exit and executed investments in AMRI (now Curia), WellDyne, Novitium, iNova, Millicent Pharma, Cadence RX, American Injectables as well as various fund investments.

Minor also serves on the Boards and leads the transaction teams on BPSC’s investments in Pharmaceutical Associates Inc., Carlin Consumer Health and Medpharm. He also currently serves as Board Observer of Eximia Research. Over the course of his career, Minor has been involved in over \$10 billion of financial transactions spanning the range of venture investing, private equity, mezzanine and senior debt, project finance debt and equity, cross boarder preferred stock issuances, sell-side, and buy-side M&A transactions (both large cap and middle market), and other corporate finance advisory assignments.

Minor began his business career in 1984 in Corporate Banking at NationsBank/Bank of America and became a Senior Relationship Manager in the Baltimore/Washington loan production office before deciding to attend business school in 1990. After an M.B.A. internship in corporate finance at The Coca Cola Company in Atlanta, Minor accepted a position as an Associate at Bowles Hollowell Conner & Company in Charlotte. Minor returned to Bank of America in 2002 to join the Strategic Investment Group, a group he eventually managed. He was then recruited to manage Corporate Development for the bank’s Global Treasury Services (\$4 billion in profit). In 2007, Minor accepted a position to join Christofferson Robb & Company to raise capital and work on the initial London project team of the firm’s 300 MW offshore wind farm (Thanet Offshore Wind Limited) which, when opened, was the world’s largest offshore wind project.

Minor received a B.A. in Economics from Davidson College in 1984, as well as an M.B.A. (honor society) in 1992 from The Kenan-Flagler Business School at UNC Chapel Hill. Most importantly, Minor has been married to his wife, Tiffany, for over 26 years and is the father of two Children – Minor (college) and Sara Frances (high school).



## Ella Grach

**CEO, Eximia Research**

Dr. Grach is the Chief Executive Officer of Eximia Research, a nationwide fully integrated clinical research network, harnessing the power of centralized platform services to deliver top-notch data within our cutting-edge clinics.

Dr. Grach is a physician scientist who is passionate about improving human health through advancements in clinical research. She has more than 25 years of experience successfully building and growing clinical research organizations and research site networks. She is a key thought leader in clinical research industry, having managed

the execution of thousands of Phase 1-3 clinical trials across multiple therapeutic areas and medical specialties.

Dr. Grach accelerated the adoption of patient-focused, decentralized clinical trials within life sciences and healthcare. She is an expert in execution and evaluation of complex clinical trials and participated in various regulatory meetings.

Throughout her career, Dr. Grach has established numerous clinical research and healthcare organizations. A recognized business leader with a demonstrated history of building and running businesses. Earlier projects with successful exits included: Research sites, Site management organization, Neuro & Sleep Diagnostic lab and the Site Network organization.

In addition to her leadership of Eximia Research, Dr. Grach is involved with several other healthcare firms as an advisor or a board member.



## Moisha Platto

CEO, Scout Clinical

Moisha Platto was appointed CEO of Scout in 2024 as the company embarks on a new era of innovation and excellence. Since joining Scout as a Strategic Advisor in 2021 and advancing to COO in 2023, Moisha has been pivotal in driving revenue, market impact, and corporate value. His strategic vision and leadership have been instrumental in Scout's rebranding and operational optimization.

Moisha's extensive experience includes his role as Chief Commercial Officer of PRA Health Sciences, where he led commercial affairs and corporate development. His blend of strategic analysis, creativity, and engaging interpersonal style continues to enhance Scout's ability to deliver exceptional client services and empower sites and patients.



## Jake Curtis

Associate, Bourne Partners

Jake joined Bourne Partners in 2022 as an Associate and provides transaction execution support on a variety of M&A transactions across the Pharma Services sector.

Before joining the team, Jake was a Senior Analyst at Crosstree Capital Partners, working in the Pharma Services group. Jake began his career with Bourne Partners when he joined the firm as an intern in 2019. He graduated from the University of North Carolina at Charlotte with a B.S. in Finance.



## Travis Allen

Interim CEO, American Injectables

Travis Allen, PharmD is the Interim CEO at American Injectables and an accomplished leader in the pharmaceutical industry with over a decade of specialized experience in sterile injectables, including biologics and small molecules. At American Injectables, he spearheads organizational growth and strategic initiatives, working to position the company as a leader in the injectables CDMO space. Travis was a founding member of American Injectables and played a pivotal role in developing the long-term growth strategies for CDMO operations.

He has a deep passion for integrating Pharma 4.0 innovations, driving industry transformation, and bringing products to market faster. His previous experiences span across business development, strategic planning, and aseptic manufacturing operations, with prior roles at Actavant Pharmaceuticals, Premier Pharmacy Labs, and Amgen.



## Jeremy Johnson

Senior Managing Director & Head of Investment Banking, Bourne Partners

Jeremy has 25 years of healthcare-focused M&A and private equity experience. He has been with Bourne Partners since 2006 and is part of the core leadership team at the firm. Jeremy currently serves as a Senior Managing Director, overseeing the broker dealer and all Investment Banking activities. Today Jeremy is focused on proactively growing the investment bank, including expanding its coverage and service offering more broadly across the healthcare and life sciences market.

Prior to Bourne Partners, Jeremy was a founding member and Managing Director at Madison Keats, a life sciences strategy and consulting firm. Jeremy began his career at VentureWorx, an Internet incubator. He is a graduate of Georgetown University where he earned a Bachelor of Arts in Economics.

Outside of work, Jeremy is active in the community. He is a member of Leadership Charlotte and an avid supporter of a few personally important charitable foundations. In addition, he remains highly active with Georgetown University. Jeremy is a native of North Carolina and currently lives in the same neighborhood in south Charlotte where he grew up. He is married to his wife, Jessica, and they have three young children who attend the same schools Jeremy attended when he was their age. When he's not chasing down a deal, Jeremy enjoys spending most of his free time with his wife and kids.



## Dr. Gavin Spencer

CEO, Nicox

Dr. Spencer serves as Chief Executive Officer of Nicox, a public French biotech company that he has been with since 2005. He has spent more than 25 years in the life sciences industry and combines strong business acumen with a solid scientific background and broad strategic, financial, corporate development, commercial and operational management experience in biotech and large pharma. During his time with Nicox, Dr. Spencer has had a key role in building and managing Nicox's partnerships, including closing agreements with Pfizer, Bausch + Lomb, VISUfarma and Ocumension Therapeutics. He has been involved in equity raising and investor

relations at Nicox for many years and has led the Company's recent financing activities, including the key royalty monetization transaction announced earlier this month with Soleus Capital. Dr. Spencer previously worked at Novartis Consumer Health and Boots Healthcare International and holds a Ph.D. in chemistry from the University of Aberdeen.



## Asher M. Rubin

Partner, Sidley Austin LLP

Asher Rubin is a Partner at Sidley Austin LLP, focusing his practice on the life sciences and healthcare industries, working with clients on complex licensing agreements, joint ventures, collaborations, capital markets raising transactions, including private and public offerings, M&A, and structured finance arrangements.

With more than 20 years of experience in the life sciences industry, Mr. Rubin has handled transactions involving some of the most innovative technologies in the life sciences industry, including CAR-T therapies, checkpoint inhibitors, co-stimulatory proteins, companion diagnostics, digital health technologies, ultra-orphan drugs, and gene therapies. Prior to joining Sidley, Mr. Rubin was a partner at another global law firm where he led the Life Sciences and Healthcare industry team for more than 10 years. Asher also served as in-house counsel and ultimately general counsel of a publicly traded, fully integrated pharmaceutical company.





## Matthew Bullard

Strategic Advisor, Bourne Partners

Matthew Bullard is an accomplished healthcare-focused investment professional with over 20 years of life sciences experience and a track record of over \$5 billion of specialized financings.

Matt is a former Managing Director at HealthCare Royalty Partners where he was responsible for identifying, structuring, and negotiating investments across royalty monetization, revenue interest financing, and debt strategies. Previously, Matt was a Partner at leading life sciences and healthcare investor NovaQuest Capital Management where he focused on product-based investments in late-stage clinical

clinical and commercial biopharma programs.

As a Strategic Advisor at Bourne Partners, Matt supports royalty monetization activities in Bourne Partners' investment banking advisory team, through deal origination, structuring, and execution.



## Oliver White

Associate, Bourne Partners

Oliver White joined Bourne Partners in 2023 and is a key member of its royalty monetization and non-dilutive financing coverage team. Prior to joining Bourne Partners, Oliver spent five years with Tanner Pharma Group (a Bourne Partners portfolio company) where he supported a range of US and European biopharma companies in facilitating access to innovative rare disease and oncology drugs for patients in countries where they are not yet commercially available.

Oliver holds an M.S. in Chemistry from the University of Durham, England. During his studies, Oliver gained industry R&D experience with Vertex Pharmaceuticals and completed his Master's research placement at Université Grenoble-Alpes, France.



## Kurt Orlofski

CEO, PAI Pharma

Kurt Orlofski has served as CEO of PAI Pharma since January 2017. A leader and turnaround CEO, Kurt has led generic pharmaceutical companies for over 20 years. From 2009 to 2016, he was President and COO of G&W Laboratories. Prior to G&W, he was President of Wockhardt USA (Apr 2007 - Aug 2009). Prior to his time with Wockhardt, he was President and Chief Executive Officer of Pliva, the US subsidiary of global specialty pharmaceutical company Pliva. He was responsible for all Pliva US businesses including USD300m of generics business.

Previously, Mr. Orlofski was Senior Vice President of Global Business Development at Alpharma Human Pharmaceuticals. His areas of expertise include pharmaceutical general management, transformational leadership, operations and quality management, sales and marketing in generics, new business unit start-ups, product acquisition, brand and generic in and out licensing of products and technology, business unit and asset sales and acquisitions (including integration), contract manufacturing deals in and out, and negotiation and execution of supplier and customer supply agreements.



## Pat Stephens, PharmD, CQA

Senior Vice President, Hims & Hers

Dr. Stephens is the Senior Vice President of Pharmacy Safety, Quality and Compliance at Hims & Hers. She received her Bachelor of Science in Pharmacy in 1993 and a Doctorate in Pharmacy in 1995 from McWhorter School of Pharmacy, in Birmingham, AL. Dr. Patricia Stephens' professional career spans three decades in the sterile compounding arena. She is a Registered Pharmacist in Alabama, North Carolina and South Carolina, and received her certification as a certified auditor (CQA) through the American Society for Quality (ASQ) in 2022. She had spent the past 18+ years growing her own business, Medi-Fare Drug Pharmaceutical Compounding, a once-

hybrid pharmacy/compounding company that is now solely dedicated to sterile processing as an FDA registered 503B Outsourcing Facility. As a senior executive and entrepreneur, Stephens lead both by personal example and by effective management of employees. She attributed her success to her company culture based on quality by design. During her tenure at Medi-Fare Drug Pharmaceutical Compounding, she and the staff, working tirelessly and in harmony, were thrilled to have become one of the first in the nation to have an FDA inspection without receiving any 483 observational findings.

After selling her 503B business in 2019, she provided consultation and audit services for both 503A and FDA regulated 503B compounding arenas, assessing them for compliance with USP guidelines, or current Good Manufacturing Practices (cGMPs), before joining the team at Hims & Hers in 2023.



## Dr. Carlos Jorge

Chief Medical Officer & Co-Founder, Companion Health

Carlos Jorge, MD, has been in healthcare for over 20 years and is the only physician in Charlotte triple board certified in family medicine, lipidology, and functional medicine & anti-aging. Carlos is committed to helping clients improve their well-being by taking a holistic approach to their care. Carlos has worked for both of Charlotte's major healthcare systems, Carolinas Healthcare System (now Atrium) and Novant Health. While at Novant, Carlos helped create Novant's corporate wellness, executive health, and heart & wellness programs.

From 2011-2019, Carlos practiced medicine as a physician co-owner of the independent family medicine practice, Ballantyne Medical Associates. In May 2019, Carlos left Ballantyne Medical Associates to start a new clinic, Companion Health. Dissatisfied with the high-volume, insurance-based model of "sick care," Carlos, along with business partner and wife Nathalie Simmons Jorge, created Companion Health to reconnect with true medicine, deliver world-class care, and help clients achieve the health and wellness they deserve.

Carlos is a graduate of Universidad Nacional Pedro Henriquez Santo Domingo Urena School of Medicine and the University of Virginia. He is bilingual in Spanish and a lifelong learner. When he is not seeing patients, he enjoys listening to music, exercising, traveling, cooking, reading, and spending time with his family.



## John Chiminski

Chairman, Catalent

John Chiminski was named Chief Executive Officer of Catalent, Inc. in March 2009 and appointed Chair of the Catalent Board in October 2016. He then served as Catalent's Executive Chair from June 2022 to June 2023, as part of a planned succession of a new CEO and transition to an independent Chair of the Catalent BoD.

Mr. Chiminski partnered with the PE firm Blackstone to complete a carve-out of the Catalent business from Cardinal Health and transform it to its current position as a market leader in biopharma services. Included in that transformation was a fully independent public company in October 2016. Under a decade of his leadership, Catalent's revenue grew 8% CAGR at constant currency and its enterprise value more than quintupled to \$18.5 billion.

Mr. Chiminski has a diversified medical diagnostics and pharmaceutical background that includes operations leadership, product development and services, with a track record of growing global businesses.

He joined Catalent after more than 20 years at GE Healthcare. From 2007 until 2009, Mr. Chiminski served as President and CEO of GE Medical Diagnostics, a global business with sales of \$1.9 billion. From 2005 to 2007, he served as Vice President and General Manager of GE Healthcare's global magnetic resonance business, and, from 2001 to 2005, Mr. Chiminski served as Vice President and General Manager of Global Healthcare Services. Earlier in his career, Mr. Chiminski held a series of cross-functional leadership positions in both operations and engineering, including GE Medical Systems assignments in France.

Mr. Chiminski holds a bachelor's degree from Michigan State University and a master's degree from Purdue University, both in electrical engineering, as well as a master's degree in management from the Kellogg School of Management at Northwestern University. In 2012, he received a Distinguished Engineering Alumni award from Purdue for his record of accomplishments. In 2019, Mr. Chiminski was the first recipient of the CPhI Lifetime Achievement Award for a distinguished career in the biotech or pharmaceutical arena. He is a Senior Advisor at Abingworth, a bioscience investment firm, and previously served as a director of PhenomeX, DJO Global as well as Graham Packaging. Married with three children, Mr. Chiminski lives in Southeastern Florida.



## Philip Macnabb

CEO, Curia

Philip Macnabb joined Curia in 2023 as Chief Executive Officer. He leads the company in the pursuit of its mission to improve patients' lives, applying end-to-end capabilities and deep scientific expertise to advance customers from idea to impact.

Phil brought more than 20 years of private-equity leadership experience to Curia, with the previous 10 years spent in the healthcare sector. Most recently, he served as Chief Executive Officer at Epselon Global, a company that he co-founded. In addition

to his healthcare experience, he has held senior positions in technology, distribution, and consumer products segments. Phil has a track record of focusing companies on their core value proposition, enhancing the customer experience and building organizations with real and sustaining value.

Phil earned an MBA from the University of Chicago, and a BS in Business Administration from Purdue University.